Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taliglucerase alfa extension in Gaucher Disease
NCT00705939Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2008
- Primary completion
- May 2012
- Modality
- Replacement Enzymes
- Countries
- 8
01
Overview
Phase 3, double-blind trial of taliglucerase alfa in Gaucher disease (GD) (3 arms), sponsored by Pfizer. Primary endpoint: Spleen Volume at 36 months. Started Jun 2008; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT00705939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705939.